ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

BCYC Bicycle Therapeutics PLC

23.10
-1.20 (-4.94%)
14 Jun 2024 - Closed
Delayed by 15 minutes
Name Symbol Market Type
Bicycle Therapeutics PLC NASDAQ:BCYC NASDAQ Depository Receipt
  Price Change % Change Price Bid Price Offer Price High Price Low Price Open Price Traded Last Trade
  -1.20 -4.94% 23.10 21.90 24.75 24.19 22.96 24.13 263,665 23:35:47

Bicycle Therapeutics to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference

07/02/2024 12:00pm

Business Wire


Bicycle Therapeutics (NASDAQ:BCYC)
Historical Stock Chart


From Dec 2023 to Jun 2024

Click Here for more Bicycle Therapeutics Charts.

Bicycle Therapeutics plc (NASDAQ:BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that management will participate in a fireside chat at the Oppenheimer 34th Annual Healthcare Life Sciences Conference on February 14, 2024, at 10 a.m. ET.

A live webcast of the fireside chat will be accessible from the Investor section of the company’s website, www.bicycletherapeutics.com. A replay of the webcast will be archived and available following the event.

About Bicycle Therapeutics Bicycle Therapeutics is a clinical-stage biopharmaceutical company developing a novel class of medicines, referred to as Bicycle® molecules, for diseases that are underserved by existing therapeutics. Bicycle molecules are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. This constraint facilitates target binding with high affinity and selectivity, making Bicycle molecules attractive candidates for drug development. The company is evaluating BT8009, a Bicycle Toxin Conjugate (BTC®) targeting Nectin-4, a well-validated tumor antigen; BT5528, a BTC targeting EphA2; and BT7480, a Bicycle TICA® targeting Nectin-4 and agonizing CD137, in company-sponsored Phase 1/2 trials. In addition, BT1718, a BTC that targets MT1-MMP, is being investigated in a Phase 1/2a clinical trial sponsored by the Cancer Research UK Centre for Drug Development. Bicycle Therapeutics is headquartered in Cambridge, UK, with many key functions and members of its leadership team located in Cambridge, Mass. For more information, visit bicycletherapeutics.com.

Investors: Stephanie Yao SVP, Investor Relations and Corporate Communications ir@bicycletx.com 857-523-8544

Media: Argot Partners Deborah Elson media@bicycletx.com 212-600-1902

1 Year Bicycle Therapeutics Chart

1 Year Bicycle Therapeutics Chart

1 Month Bicycle Therapeutics Chart

1 Month Bicycle Therapeutics Chart

Your Recent History

Delayed Upgrade Clock